126
Participants
Start Date
August 31, 2017
Primary Completion Date
August 29, 2018
Study Completion Date
January 31, 2021
BCD-100
Anti-PD-1 monoclonal antibody
"State Budgetary Institution of Healthcare of the Arkhangelsk Region Arkhangelsk Regional Clinical Oncology Dispensary (SBHI AR ARCOD)", Arkhangelsk
"N.N. Blokhin Russian Cancer Research Center", Moscow
"State Budgetary Healthcare Institution Moscow Clinical Scientific Center funded by Moscow Health Department (SBHI MCSC MHD)", Moscow
"Pavlov First Saint Petersburg State Medical University", Saint Petersburg
"Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)", Saint Petersburg
"Federal State Budgetary Institution N.N. Petrov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation (FSBI N.N. Petrov RIO (Chemotherapy Department with Innovative Technologies)", Saint Petersburg
"Federal State Budgetary Institution N.N. Petrov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation, Research Department of the Innovative Methods of Therapeutic Oncology and Rehabilitation (FSBI N.N. Petrov RIO of the", Saint Petersburg
LLC BioEk, Saint Petersburg
"State Budgetary Institution of Healthcare Clinical Oncology Dispensary of Chelyabinsk Region (SBIH CODCR)", Saint Petersburg
Lead Sponsor
Biocad
INDUSTRY